SCHEMBL7528541

SCHEMBL7528541

CSc1ccc(NS(=O)(=O)C(F)(F)F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 1/20 0.61
PTPN1 P18031 1/20 0.58
SMN1; SMN2 Q16637 4/20 0.57
MAPK1 P28482 3/20 0.57
CA2 P00918 4/20 0.56
ALDH1A1 P00352 9/20 0.54
MAPT P10636 5/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
ALOX12 P18054 1/20 0.51
CA1 P00915 2/20 0.50
HTT P42858 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
LMNA P02545 2/20 0.44
TSHR P16473 2/20 0.44
GAA P10253 1/20 0.44
ALOX15 P16050 1/20 0.44
ESR1 P03372 1/20 0.42
HSPD1 P10809 1/20 0.41
HSPE1 P61604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28027003 0.79 PTPN1 (0.54) PTPN11PTPN1SMN1; SMN2MAPK1CA2
SCHEMBL13690232 0.79 PTPN11 (0.67) PTPN11PTPN1SMN1; SMN2MAPK1CA2
SCHEMBL17774980 0.79 PTPN11 (0.67) PTPN11PTPN1SMN1; SMN2MAPK1CA2
SCHEMBL14799102 0.76 ALDH1A1 (0.58) SMN1; SMN2MAPK1CA2ALDH1A1MAPT
SCHEMBL7527132 0.76 PTPN1 (0.66) PTPN11PTPN1SMN1; SMN2MAPK1CA2
SCHEMBL7525890 0.76 CA2 (0.68) PTPN11PTPN1SMN1; SMN2MAPK1CA2
SCHEMBL7528321 0.76 PTPN11 (0.79) PTPN11PTPN1SMN1; SMN2MAPK1CA2
SCHEMBL11121097 0.75 PTPN11 (0.72) PTPN11PTPN1SMN1; SMN2MAPK1CA2
SCHEMBL6881190 0.75 PTPN1 (0.63) PTPN11PTPN1SMN1; SMN2MAPK1CA2
SCHEMBL3155581 0.75 PTPN1 (0.63) PTPN11PTPN1SMN1; SMN2MAPK1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6472145-B2 A MOBILE IONOPHORE COMPOSITION EFFECTIVE TO MODULATE APP CATABOLISM WITHOUT SUBSTANTIALLY ALTERING THE VIABILITY OF APP-CONTAINING CELLS; INHIBITS AMYLOID DEPOSITION; ALZHEIMER'S DISEASE; NONTOXIC THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2002-10-29 US claimed
US-20020045621-A1 Method and composition for modulating amyloidosis THE UNIVERSITY OF BRITISH COLUMBIA 2002-04-18 US claimed
US-6221667-B1 PACKAGED PHARMACEUTICAL COMPOSITION INCLUDES A MOBILE IONOPHORE WHICH PREVENTS OR DECREASES AMYLOID PRECURSOR PROTEIN CATABOLISM IN CELLS WITHOUT ALTERING CELL VIABILITY IN A PHARMACEUTICAL VEHICLE IN A CONTAINER, AND INSTRUCTIONS THE UNIVERSITY OF BRITISH COLUMBIA 2001-04-24 US claimed
EP-1077706-A1 IONOPHORE CONTAINING COMPOSITION FOR MODULATING AMYLOIDOSIS UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-02-28 EP claimed
WO-1999059597-A1 IONOPHORE CONTAINING COMPOSITION FOR MODULATING AMYLOIDOSIS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 1999-11-25 WO claimed
US-5981168-A Method and composition for modulating amyloidosis THE UNIVERSITY OF BRITISH COLUMBIA (CA) 1999-11-09 US claimed
US-6221667-B1 PACKAGED PHARMACEUTICAL COMPOSITION INCLUDES A MOBILE IONOPHORE WHICH PREVENTS OR DECREASES AMYLOID PRECURSOR PROTEIN CATABOLISM IN CELLS WITHOUT ALTERING CELL VIABILITY IN A PHARMACEUTICAL VEHICLE IN A CONTAINER, AND INSTRUCTIONS THE UNIVERSITY OF BRITISH COLUMBIA 2001-04-24 US disclosed
EP-1077706-A1 IONOPHORE CONTAINING COMPOSITION FOR MODULATING AMYLOIDOSIS UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-02-28 EP disclosed
WO-1999059597-A1 IONOPHORE CONTAINING COMPOSITION FOR MODULATING AMYLOIDOSIS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 1999-11-25 WO disclosed
US-5981168-A Method and composition for modulating amyloidosis THE UNIVERSITY OF BRITISH COLUMBIA (CA) 1999-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045621-A1 Method and composition for modulating amyloidosis APP, PSEN1, PSEN2 PTPN11 3796/4885PTPN1 3636/4885SMN1; SMN2 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.